SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is surging in community discussions as investors rally behind its organic growth model and active engagement, which is currently focused on regaining its ticker and chart status on major financial platforms. Supporters are framing this as a patient, long-term building project that stands in contrast to the volatility and rug-pull risks often associated with similar meme-themed assets.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently the subject of intense retail and institutional debate, driven by a rare public endorsement from President Trump that triggered a volatile liquidity event amidst broader concerns over AI software valuations. Investors are actively split between those who view the pullback as a buying opportunity based on the company's entrenched government contracts, and skeptics who highlight potential sector-wide rotation out of crowded SaaS and AI-linked positions.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending as investors react to a strong quarterly earnings report that exceeded revenue expectations, fueled by rising demand for its edge infrastructure and security solutions amid the rapid expansion of AI agents. Community sentiment is mixed between those celebrating the stock's significant post-earnings recovery and cautious traders debating whether the software sector's recent volatility and valuation pressures will limit further upside.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow (NOW) is experiencing a sharp sell-off driven by a UBS downgrade and deepening investor anxiety regarding the potential impact of AI disruption on traditional enterprise software business models. The stock has seen massive volume and heavy put activity as the community debates whether this is a structural repricing of the SaaS sector or a tactical buying opportunity fueled by sentiment exhaustion and extreme oversold conditions.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is currently the center of intense debate as investors weigh whether the recent sell-off represents a structural reset or a temporary exhaustion event amid fears of AI-driven disruption. While some traders point to deeply oversold technical levels and institutional accumulation as signs of a potential bottom, others argue that valuation compression and the rise of competitive AI models continue to create significant headwinds for traditional SaaS business models.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing aggressive volatility and intense debate, driven by a rapid price surge that has triggered a divide between retail momentum traders and short sellers questioning the company's valuation against its current revenue. The community is actively discussing the stock's parabolic move, the impact of a new capital-raising program, and conflicting perspectives on whether the semiconductor testing equipment maker is an overextended speculative bubble or a long-term play on silicon photonics and AI infrastructure.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened volatility and intense social media discussion as the community reacts to the sentencing of co-founder Do Kwon and persistent rumors regarding exchange delistings and potential token burns. Investors remain deeply divided, with many debating the project's long-term viability under community governance while others leverage the price action to accumulate positions in anticipation of a potential revival.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Arbitrum is currently seeing significant community interest driven by its expanding role in tokenized real-world assets (RWA), particularly following high-profile integrations with Robinhood for stock tokenization and support for PayPal's stablecoin. While traders are actively debating the impact of ongoing token unlocks and broader Layer 2 competition, sentiment remains split between those focused on its robust network utility as an Ethereum scaling leader and those concerned by recent bearish price action and supply dilution.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is facing heightened volatility and downward price pressure as investors weigh mixed earnings results and cautious guidance against the backdrop of a broader cybersecurity sector sell-off. While the community remains deeply polarized, discussions are heavily focused on the company's long-term potential as an acquisition target, the impact of AI-driven competition, and ongoing debates regarding management's compensation and capital allocation.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a massive $21 billion contract expansion with Meta through 2032 and a new multi-year agreement to provide AI infrastructure for Anthropic. While the community is heavily debating the company's aggressive debt-fueled expansion and ongoing convertible note offerings, investors remain focused on the company's dominant role in the AI compute arms race and its growing backlog of blue-chip partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alto Neuroscience (NYSE:ANRO) Trading Down 6.3%  - Time to Sell?

Alto Neuroscience (NYSE:ANRO) Shares Down 6.3% - What's Next...

Q1 Earnings Estimate for ANRO Issued By HC Wainwright

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Alto Neuroscience in a research note issued on Thursday...

Alto Neuroscience (NYSE:ANRO) Given New $38.00 Price Target at Robert W. Baird

Robert W. Baird decreased their price target on shares of Alto Neuroscience from $41.00 to $38.00 and set an "outperform" rating on the stock in a research note on Thursday...

<ul class="summary-bullets"><li>H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience.</li><li>Baird cut Alto’s price target to $38 from $41 but said the company’s depression pipeline remains the key driver of its valuation.</li><li>Jones Research’s latest price target implies a potential 100% upside to the stock’s current price.</li></ul>Shares of Alto Neuroscience (ANRO) slid about 7% on Thursday after disappointing results from a schizophrenia treatment study prompted multiple brokerages to become more cautious on the stock.On Wednesday, Alto Neuroscience <a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-schizophrenia-study-fails/cZ7HygQRIFi">said</a> its experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 Proof-of-Concept study. ALTO-101 did not show meaningful improvements in brain activity or cognitive measures compared to placebo.As a result, the biotech firm will not continue developing the drug for this use and will shift focus to other programs, including ALTO-207 for treatment-resistant depression. The company is also exploring partnership opportunities for a modified version of ALTO-101 that showed better safety and drug behavior.<h2 class="st-heading-2">Analyst Sees Pullback As Attractive Entry Point</h2>Jones Research cut Alto Neuroscience’s price target to $44 from $49, but kept a ‘Buy’ rating, according to The Fly. This implies a potential 100% upside to the stock’s current price of around $22.Analyst Justin Walsh said that while the stock’s weakness is justified, the market is underestimating Alto’s broader pipeline and sees the pullback as an attractive entry point.H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience, as the program was not a key part of its valuation, according to The Fly. The brokerage also highlighted the company’s strong cash position of $275 million, which supports its pipeline. H.C. Wainwright maintained its ‘Buy’ rating and $50 price target.Baird cut the company’s price target to $38 from $41 and maintained an ‘Outperform’ rating. Analyst Brian Skorney called the ALTO-101 Phase 2 failure disappointing, though expectations were already modest given the challenges in schizophrenia treatment. The firm said Alto’s depression pipeline remains the key driver of its valuation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/ANRO">ANRO</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user had expected a bigger drop.<stembedurl>http://stocktwits.com/Stef_DL/message/649289943</stembedurl>Year-to-date, the stock has gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/snbr-stock-on-track-to-decline-for-12th-straight-session/cZ7x67bRI8o">SNBR Stock On Track To Decline For 12th Straight Session – Retail Sees Buying Opportunity If Stock Dips Below $1</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point

Alto Neuroscience’s experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 study, leading to price target cuts from multiple brokerages.

Equity

HC Wainwright Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)

HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Alto Neuroscience in a research note on Thursday...

JonesTrading Issues Pessimistic Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price

JonesTrading reduced their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a "buy" rating on the stock in a research report on Thursday...

Alto Neuroscience (NYSE:ANRO) Shares Gap Down After Analyst Downgrade

Alto Neuroscience (NYSE:ANRO) Shares Gap Down After Analyst Downgrade...

Wedbush Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $21.00

Wedbush reduced their target price on Alto Neuroscience from $22.00 to $21.00 and set a "neutral" rating on the stock in a report on Thursday...

Alto Neuroscience (NYSE:ANRO) Earns Buy Rating from Chardan Capital

Chardan Capital reissued a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Thursday...

Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other stocks also falling in pre-market trading.read more...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

ANRO
Alto Neuroscience Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ANRO News

ANROAlto Neuroscience Inc.